Rationale for CELG at $275 / SH by 2017 :The consensus of 27 leading analysts reporting to Capital IQ forecast Celgene Corp's long-term earnings growth at 21.9%. Celgene Corp has low long-term debt at 19% of capital. Celgene Corp is currently trading at a P/E of 23.2, which is inside the value corridor (defined by the five orange lines) of a maximum P/E of 26.2. If the earnings materialize as forecast, Celgene Corp's True Worth™ valuation would be $275.69 at the end of 2017, which would be a 24.9% annual rate of return from the current price.http://seekingalpha.com/article/437391-celgene-healthy-growth-rate-and-valuation-offers-a-profitable-prescription-for-above-average-future-returns?source=yahoo
I can't speculate about the share price in 2017, but believe its possible CELG gets acquired before then. Not sure how / if that calculates into your projections. Long CELG and wish I owned much more.
CELG presently in the sweet spot of its growth; Should be easily moved into the $50B market cap area, IMHO.GLTA
No one can predict 2017, but you could be in a lot worse stocks that CELG. Buy, add or hold and hide this one in your sock draw while you sleep better at night owning.
$200 / SH would value CELG @ under $90B;Geez, Roche paid $46.8B for 44 Perecnt of Genentech !?!?http://www.reuters.com/article/2009/03/12/us-roche-genentech-sb-idUSTRE52B1DN20090312